Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

News

Local MSD idea goes global

Posted 10 October 2019

A medication adherence platform developed by MSD in Australia a decade ago is now being used in 16 countries, the company reported this week.

MSD's Corporate Responsibility report for 2018-19 shows the SPARTA program, developed in Australia in 2009 in partnership with physicians and pharmacists who wanted more robust patient support, has grown exponentially in the past 10 years with plans for further growth in 2019.

Initially expanded in the Asia-Pacific, SPARTA was used by 60,000 patients in 2013 and grew to support more than 270,000 patients across the globe in 2018.

In 2019, the program is being expanded further into the new therapeutic areas of immunology, oncology, hepatitis, HIV, women's health and insomnia.

SPARTA provides modules that support patients on any MSD drug to improve adherence and provide access to various tools and resources to assist in the management of their condition.

The modules consisted of various patient touch points providing telephone support and text/email reminders, remote monitoring, symptom management tools and disease education to help patients understand their condition better, realize the importance of diet and exercise in managing their condition and, ultimately, improve medication adherence.

"Here at MSD Australia, we are focussed on innovative ways to enhance the patient experience and the quality use of medicines - SPARTA is one example of that," a spokesperson for the company said.

"We are pleased that this program is now benefitting patients around the world."

SPARTA is available to patients in Australia, India, Indonesia, Vietnam, Malaysia, Singapore, Oman, Taiwan, Mexico, United Arab Emirates, Chile, Sweden, Belgium, Switzerland, Ireland and Germany.

Megan Brodie

Top of the Hill
The pill or the cure
New gene therapies a challenge for payers.
Approvals Action
Novartis' newest drug
First-ever oral SPMS drug Mayzent arrives.
Pipeline Monitor
New Takeda, AbbVie results
Positive data on vaccine and arthritis drug.